CHDI
SageBionetworks launches international neurobiology partnerships
Seattle, WA Sage Bionetworks has begun projects to build advanced computational models of neurobiological disease through ongoing partnerships with CHDI Foundation and Takeda Pharmaceutical Company. Analyses and the resulting models will be deposited ...Read More
CHDI Foundation, Inc. and Siena Biotech SpA enter collaboration to validate novel therapeutic targets for Huntington’s disease
New York City, NY & Siena, Italy – CHDI Foundation, Inc. (CHDI) and Siena Biotech SpA have announced a collaboration to explore and validate molecular targets that could have therapeutic potential in Huntington’s disease (HD). CHDI, a not-fo ...Read More
Enroll HD Frequently Asked Questions
By Research Participants:
- What will happen between now and July 1st 2011 – do I still attend my REGISTRY/COHORT visit? Yes. Please attend your scheduled REGISTRY or COHORT visit. Your continued ...Read More
Enroll-HD – A Prospective Registry Study in a Global HD Cohort
New York, NY; CHDI Foundation, Inc., today announced the start of a planning and consultation process to combine the existing REGISTRY and COHORT longitudinal clinical observation studies of Huntington’s disease (HD) into a worldwide initiative ca ...Read More
Alnylam, Medtronic, and CHDI Foundation Form Collaboration to Advance RNAi Therapeutics for the Treatment of Huntington’s Disease
Cambridge, Mass., Minneapolis, and New York City – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Medtronic Inc. (NYSE:MDT), and CHDI Foundation, Inc., announced today that they have formed a collaboration to advance ALN-HTT, a novel drug-device ...Read More
The Public Library of Science, with support from CHDI Foundation Inc., has launched PLoS Currents: Huntington Disease
PLoS Currents is expanding September 2, 2010,PLoS (Public Library of Science, ...Read More
CHDI Foundation, Inc. and the National Institute of Neurological Disorders and Stroke (NINDS) launch joint program to support the validation of novel therapeutic targets for Huntington’s disease
New York City, NY - CHDI Foundation, Inc. (CHDI) and the National Institute of Neurological Disorders and Stroke (NINDS) have released a funding opportunity announcement (FOA) regarding an extramural program to preclinically validate therapeutic targ ...Read More
CHDI Foundation, Inc to carry out High Q Foundation’s research activities in Huntington’s disease
CHDI, Inc., recently renamed CHDI Foundation, Inc., and High Q Foundation, Inc. announced that CHDI has taken over primary responsibility for the types of Huntington’s disease research projects previously funded by High Q. CHDI will now b ...Read More